SAFETY DATA SHEET

* 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND OF THE COMPANY/UNDERTAKING

Material VELTIN GEL

Synonym(s) VELTIN (CLINDAMYCIN PHOSPHATE AND TRETINOIN) GEL, 1.2% / 0.025% * CLINDAMYCIN - TRETINOIN GEL (CLINDAMYCIN 1% - TRETINOIN 0.025%) * FORMULATION CODE: R0843-r3 * STIEFEL PRODUCT * CLINDAMYCIN PHOSPHATE AND TRETINOIN, FORMULATED PRODUCT

Recommended Use Medicinal Product

Note This safety data sheet is written to provide health, safety and environmental information for people handling this formulated product in the workplace. It is not intended to provide information relevant to medicinal use of the product. In this instance patients should consult prescribing information/package insert/product label or consult their pharmacist or physician. For health and safety information for individual ingredients used during manufacturing, refer to the appropriate safety data sheet for each ingredient.

Company Name

Stiefel Laboratories, Inc. (a GSK company)
GlaxoSmithKline UK
980 Great West Road
Brentford, Middlesex TW8 9GS UK
UK General Information (normal business hours): +44-20-8047-5000

GlaxoSmithKline US
5 Moore Drive
Research Triangle Park, NC 27709 USA
US General Information (normal business hours): +1-888-825-5249

Email Address: msds@gsk.com
Website: www.gsk.com

EMERGENCY PHONE NUMBERS -

TRANSPORT EMERGENCIES (by country / geographic region):

Africa / EU / Israel / Middle East (English / European languages):	+44 (0) 1235 239 670
Asia Pacific (except China):	+65 3158 1074
China:	+86 10 5100 3039
Middle East / Africa (Arabic-speaking countries):	+44 (0) 1235 239 671
US:	+1 703 527 3887

available 24 hrs/7 days; multi-language response

MEDICAL EMERGENCIES: +1 612 221 3999, Ext 221
available 24 hrs/7 days; multi-language response

2. HAZARDS IDENTIFICATION

Health

Caution - Pharmaceutical agent.
Caution - The toxicological properties of this material have not been fully investigated.
Not expected to be a health hazard during normal handling.
Health effects information is based on hazards of components.
Contains one or more components, categorised as potentially harmful to the development of unborn offspring.
Overexposure might lead to increased sensitivity of the skin to ultraviolet radiation and sunlight.
Exposure might occur via ingestion; skin; eyes.

Environment No information is available about the potential of this product to produce adverse environmental effects.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Ingredients	CAS #	Percent	EC-No.
CLINDAMYCIN PHOSPHATE	24729-96-2	1.0	246-433-0
LAURETH-4	5274-68-0	3.0	226-097-1
RETINOIC ACID	302-79-4	0.025	206-129-0
Other components below reportable levels		>95.0	

4. FIRST-AID MEASURES

Ingestion Never attempt to induce vomiting. Do not attempt to give any solid or liquid by mouth if the exposed subject is unconscious or semi-conscious. Wash out the mouth with water. If the exposed subject is fully conscious, give plenty of water to drink. Obtain medical attention.

Inhalation Physical form suggests that risk of inhalation exposure is negligible.

Skin contact Using appropriate personal protective equipment, remove contaminated clothing and flush exposed area with large amounts of water. Obtain medical attention if skin reaction occurs, which may be immediate or delayed.

Eye contact Wash immediately with clean and gently flowing water. Continue for at least 15 minutes. Obtain medical attention.

NOTES TO HEALTH PROFESSIONALS

Medical Treatment Treat according to locally accepted protocols. For additional guidance, refer to the current prescribing information or to the local poison control information centre.

Medical Conditions Caused or Aggravated by Exposure Refer to prescribing information for detailed description of medical conditions caused by or aggravated by overexposure to this product.

Health Surveillance Procedures Pre-placement and periodic health surveillance is not usually indicated. The final determination of the need for health surveillance should be determined by local risk assessment.

Antidotes No specific antidotes are recommended.

5. FIRE-FIGHTING MEASURES

Fire and Explosion Hazards Not expected for the product, although the packaging is combustible.

Extinguishing Media No special requirements needed.

Special Firefighting Procedures For single units (packages): No special requirements needed.
For larger amounts (multiple packages/pallets) of product: Since toxic, corrosive or flammable vapours might be evolved from fires involving this product and associated packaging, self contained breathing apparatus and full protective equipment are recommended for firefighters.
If possible, contain and collect firefighting water for later disposal.

Hazardous Combustion Products Toxic, corrosive or flammable thermal decomposition products are expected when the product is exposed to fire.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions Wear protective clothing and equipment consistent with the degree of hazard.

Environmental Precautions For large spills, take precautions to prevent entry into waterways, sewers, or surface drainage systems.

Clean-up Methods Collect and place it in a suitable, properly labelled container for recovery or disposal.

Decontamination Procedures No specific decontamination or detoxification procedures have been identified for this product.

7. HANDLING AND STORAGE

HANDLING

GSK Process Hazard Category	1
General Requirements	No special control measures required for the normal handling of this product. Normal room ventilation is expected to be adequate for routine handling of this product.

STORAGE No storage requirements are considered necessary for the control of fire and explosion hazards.

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

OCCUPATIONAL EXPOSURE LIMITS

INGREDIENT	RETINOIC ACID	
GSK Occupational Hazard Category	4	
GSK Occupational Exposure Limit	4 mcg/m3 (8 HR TWA)	REPRODUCTIVE HAZARD

Other Equipment or Procedures None required for normal handling. Wash hands and arms thoroughly after handling.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance

Colour	Yellow.
Physical Form	Gel.

10. STABILITY AND REACTIVITY

Stability This product is expected to be stable.

Conditions to Avoid None for normal handling of this product.

11. TOXICOLOGY INFORMATION

Pharmacological Effects This product contains active ingredient(s) with the following activity: a retinoid (vitamin A derivative); an antibiotic.

Target Organ Effects No specific target organ effects have been identified.

Routes of Exposure

Oral Toxicity	Not expected to be toxic following ingestion. Assessment based upon effects of individual components.
Inhalation Toxicity	No studies have been conducted.
Skin Effects	Irritation is not expected following direct contact. Assessment based upon effects of individual components.
Eye Effects	Irritation is not expected following direct contact with eyes. Assessment based upon effects of individual components.

Sensitisation Sensitisation (allergic skin reaction) is not expected.

Genetic Toxicity Not expected to be genotoxic, based on effects of individual components.

Carcinogenicity No components are listed as carcinogens by GSK, IARC, NTP or US OSHA.

Reproductive Effects Not expected to produce adverse effects on fertility or development under occupational exposure conditions.
Contains components which have been classified as: Possible risk of toxicity in developing human offspring.

Other Adverse Effects Overexposure might lead to increased sensitivity of the skin to ultraviolet radiation and sunlight.

12. ECOLOGICAL INFORMATION

Summary This material contains an active ingredient that has been tested and which may be harmful if released directly to the environment. Consult the MSDS of the active ingredient for specific information about potential environmental effects. Local regulations and procedures should be consulted prior to environmental release.

13. DISPOSAL CONSIDERATIONS

Disposal Recommendations Collect for recycling or recovery if possible. The disposal method for rejected products/returned goods must ensure that they cannot be re-sold or re-used.

Regulatory Requirements Observe all local and national regulations when disposing of this product.

14. TRANSPORT INFORMATION

The SDS should accompany all shipments for reference in the event of spillage or accidental release. Only authorised persons trained and competent in accordance with appropriate national and international regulatory requirements may prepare dangerous goods for transport.

UN Classification and Labelling

Transport Information Not regulated in transport.

15. REGULATORY INFORMATION

The information included below is an overview of the major regulatory requirements. It should not be considered to be an exhaustive summary. Local regulations should be consulted for additional requirements.

EU Classification and Labelling

Exempt from requirements of EU Dangerous Preparations directive - product regulated as a medicinal product, cosmetic product or medical device.

US OSHA Standard (29 CFR Part 1910.1200)

Classification Exempt when packaged for sale to consumers in a retail establishment.

Other US Regulations

TSCA Status Exempt

16. OTHER INFORMATION

References GSK Hazard Determination

SDS Version Number 2

SDS Sections Updated

Sections	Subsections
IDENTIFICATION OF SUBSTANCE / PREPARATION AND OF COMPANY	

The information and recommendations in this safety data sheet are, to the best of our knowledge, accurate as of the date of issue. Nothing herein shall be deemed to create any warranty, express or implied. It is the responsibility of the user to determine the applicability of this information and the suitability of the material or product for any particular purpose.